Shares in Glaukos (NYSE:GKOS) have fallen today after the diabetes-focused medical device maker missed expectation on Wall Street with its 2nd quarter earnings results. The San Clemente, Calif.-based company posted losses of $3.3 million, or 10¢ per share, on sales of $41.3 million for the 3 months ended June 30, seeing profits swing 241.6% into losses […]
Boston Scientific to end Renuvia bioresorbable coronary stent program
Boston Scientific (NYSE:BSX) is looking to terminate its Renuvia bioresorbable coronary stent program, according to a Minneapolis Star Tribune report. The move comes after new clinical studies of Abbott‘s (NYSE:ABT) Absorb bioresorbable stent indicated that use of the device resulted in a higher risk of serious adverse events compared to metal stents. Marlborough, Mass.-based Boston Scientific said that while the […]
Brainstorm Cell Therapeutics wins $16m grant for pivotal NurOwn ALS study
Brainstorm Cell Therapeutics (NSDQ:BCLI) said today it won a $16 million grant from the California Institute of Regenerative Medicine to engage in a phase 3 study of its NurOwn mesenchymal stem cell-based platform for treating amyotrophic lateral sclerosis. Brainstorm said it is in the advanced stages of planning a Phase 3 clinical trial investigating NurOwn for […]
Bonesupport closes $57m IPO
BoneSupport said last week it closed its initial public offering, raising a total of approximately $57.1 million (SEK 500 million), not including an over-allotment option. The Swedish company, which is developing the Cerament G injectable antibiotic-eluting bone graft substitute, said it floated approximately 17.2 million new shares at $3.40 per share (SEK 29) in the […]
Sirtex shares jump on restructuring plan, 15% headcount reduction
Sirtex Medical (ASX:SRX) saw shares jump today after revealing plans for a major restructuring as the company looks to cut its headcount and focus on its “profitable core business.” The company said it underwent an “extensive review of the business” to identify where it could improve efficiencies. The review led to an initial $7 million […]
Rhythm, Camurus tout early data on setmelanotide in rare genetic obesity
Camurus (STO:CAMX) and biopharma group Rhythm today released initial results from an ongoing Phase 1A clinical trial examining the pharmacokinetics and tolerability of an extended-release formulation of setmelanotide. The drug formulation uses Camurus’ FluidCrystal injection depot drug delivery technology to deliver Setmelanotide, Rhythm’s novel melanocortin-4 receptor agonist designed to treat genetic disorders of obesity. Initial results […]
Theraclion partner UVA wins FDA nod for combined HIFU, immunotherapy breast cancer trial
Theraclion said yesterday its academic development partner, the University of Virginia, won an FDA nod to launch a study of the combined use of echotherapy high intensity focused ultrasound and immunotherapy drug pembrolizumab for treating patients with breast cancer. The study will examine the combined treatment’s effect on fighting breast cancer tumor cells, the French […]
Baxter integrates DoseEdge with Epic’s Willow pharmacy system
Baxter (NYSE:BAX) said today it will integrate its DoseEdge Pharmacy workflow manager with the Epic Willow Impatient Pharmacy system. The Deerfield, Ill.-based company said that the bi-directional integration between the dedicated intravenous workflow system and electronic medical records to help hospitals meet compliance requirements with the Centers for Medicare & Medicaid Services and other payors. “Every time […]
Icon Bioscience touts FDA NDA submission for Dexycu
Icon Bioscience said today that the FDA accepted the company’s submitted new drug application for its Dexycu drug designed to be used as an anti-inflammatory following cataract surgery. The Newark, Calif.-based company’s Dexycu utilizes the company’s Verisome novel drug delivery system designed to treat ophthalmic diseases and slowly release the drug while the Verisome system […]
Medtronic inks diabetes deal with Aetna
Medtronic (NYSE:MDT) said today that it inked a deal with health insurer Aetna (NYSE:AET) to measure outcomes for patients with Type 1 and Type 2 diabetes on multiple daily insulin injections. The program is designed for patients who elect to move to an insulin pump, using a Medtronic pump with its SmartGuard tech and its […]